The Centers for Medicare and Medicaid Services (CMS) has initiated the Bridge demonstration program, granting eligible Medicare beneficiaries access to GLP-1 receptor agonists for the treatment of obesity.

美國醫療保險和醫療補助服務中心（CMS）已啟動 Bridge 示範計畫，使合資格的 Medicare 受益人能夠使用 GLP-1 受體激動劑治療肥胖症。

The Bridge program establishes a temporary regulatory mechanism to circumvent existing federal prohibitions on Medicare coverage for obesity-specific medications. Under this framework, eligible beneficiaries—defined as individuals with a body mass index (BMI) of 35 or higher, or those with lower BMIs presenting comorbidities such as prediabetes or cardiovascular dysfunction—may access GLP-1 therapies via a standardized $50 monthly copayment. This funding is derived from taxpayer allocations rather than private Part D insurers. The operational administration of prior authorizations has been contracted to Humana, though clinical eligibility must be certified by healthcare providers.

Bridge 計畫建立了一套臨時監管機制，以規避現行聯邦政府禁止 Medicare 承保肥胖專用藥物的規定。在此框架下，合資格受益人（定義為身體質量指數 (BMI) 達 35 或以上，或 BMI 較低但患有糖尿病前期的心血管功能障礙等併發症者）可透過每月 50 美元的標準共付額使用 GLP-1 療法。此項資金源於納稅人撥款，而非私營 Part D 保險公司。預先授權的運作管理已承包給 Humana，但臨床資格必須由醫療保健提供者認證。

From a market perspective, the program facilitates a significant expansion of the addressable patient population for Novo Nordisk and Eli Lilly. Analysts project that the inclusion of these medications could generate annual revenues exceeding one billion dollars per firm, with a particular emphasis on the adoption of oral formulations among the geriatric demographic. However, the transition to this model may induce systemic strain on clinical and pharmaceutical infrastructure due to an anticipated surge in demand.

從市場角度來看，該計畫顯著擴大了 Novo Nordisk 和 Eli Lilly 的潛在患者群體。分析師預計，將這些藥物納入計畫可為每家公司創造每年超過 10 億美元的收入，特別是老年族群對口服製劑的採納。然而，轉向此模式可能會因需求預期激增，而對臨床及藥房基礎設施造成系統性壓力。

Institutional instability persists regarding the long-term viability of this coverage. The Bridge program is scheduled to terminate at the end of 2027 unless legislative intervention occurs or the subsequent 'Balance' program achieves voluntary adoption by private insurers. The latter remains precarious, as insurers have expressed reservations concerning cost structures. Furthermore, reports indicate a divergence between the administration's intended pricing strategy—which sought lower costs in exchange for increased volume—and the actual outcomes, as certain pricing contingencies remained unmet due to the lack of universal private insurer participation.

關於此項保障的長期可行性，制度上仍不穩定。除非有立法干預，或隨後的「Balance」計畫獲得私營保險公司的自願採納，否則 Bridge 計畫預計將於 2027 年底終止。後者仍不確定，因為保險公司對成本結構表示保留。此外，報告指出政府原定的定價策略（旨在透過增加銷量以換取低成本）與實際結果之間存在分歧，由於缺乏私營保險公司的全面參與，某些定價條件未能達成。

The Bridge program provides immediate, subsidized access to obesity medications for millions of seniors, though its temporary nature creates clinical uncertainty regarding long-term treatment continuity.

Bridge 計畫為數百萬名長者提供了即時且有補貼的肥胖藥物管道，但其臨時性質對長期治療的連續性造成了臨床上的不確定性。